TanoMed

Immunotherapy Solutions for GI Cancers

Health Tech & Life Sciences
Stealth Mode
Pre-Funding Herzliya, Israel Founded 2020
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2020
Headcount
6
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

TanoMed is developing immune cell-targeted nanodelivery solutions designed to improve therapeutic efficacy by triggering tumor destruction following T- and B-cell priming. TanoMeds precision immuno-oncology therapy is based on a novel dendritic cell-targeted nano-immunomodulator platform that combines antigen-carrying capacity with in vivo targeting and modulation of DC function, thereby expanding the host antitumor specific T-effector phenotype and improving sensitivity and long-term tumor recognition.

Q&A

What is TanoMed's primary focus?
TanoMed is developing immunotherapy solutions for gastrointestinal cancers, specifically immune cell-targeted nanodelivery solutions to improve therapeutic efficacy by triggering tumor destruction.
When was TanoMed founded?
TanoMed was founded in August 2020.
What is the current status of TanoMed?
TanoMed is currently inactive, having ceased operations in February 2022.
Where is TanoMed headquartered?
TanoMed is headquartered in Herzliya, Center District, Israel.
Who are the co-founders of TanoMed?
The co-founders of TanoMed are Helena Florindo and Ronit Satchi-Fainaro.
What is TanoMed's current funding stage?
TanoMed is in the Pre-Funding stage.
What sector does TanoMed operate in?
TanoMed operates primarily in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Team · 2

Founder · Co-founder
LinkedIn ↗
Founder · Co-founder & CSO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B2C

Tags

cancerimmunotherapypharma-companiesoncologynanotechnologygastroenterologybiotechnologycancer-therapypersonalized-medicinestealthmode
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2020-8
Employees (exact)6
Status reasonNon Active, Feb 2022 ceased to operate